Form 8-K - Current report:
SEC Accession No. 0001193125-24-205350
Filing Date
2024-08-22
Accepted
2024-08-22 16:05:32
Documents
14
Period of Report
2024-08-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d888554d8k.htm   iXBRL 8-K 48691
2 EX-10.1 d888554dex101.htm EX-10.1 88839
  Complete submission text file 0001193125-24-205350.txt   288387

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20240820.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20240820_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20240820_pre.xml EX-101.PRE 11268
16 EXTRACTED XBRL INSTANCE DOCUMENT d888554d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 241232007
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)